New drug rezvilutamide takes on enzalutamide in prostate cancer showdown
NCT ID NCT07241416
First seen Nov 21, 2025 · Last updated Jun 07, 2026 · Updated 25 times
Summary
This phase 3 study tests whether a new drug, rezvilutamide, works better than the standard drug enzalutamide for men with low-volume metastatic hormone-sensitive prostate cancer. Both drugs are combined with hormone therapy (ADT). The study aims to see which treatment lowers PSA levels more effectively. About 206 men will participate, and all will receive active treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.